Explore our Services
Enaas holds a Bachelor of Arts in Medical Anthropology from the University of Virginia. She is skilled in clinical comprehension and has experience producing research in healthcare, specializing in indigenous health and biopolitics.
Dobson | DaVanzo attended the Wound Care Evidence Summit from May 19th - May 20th 2022, organized by the Alliance of Wound Care Stakeholders.
The summit convened a multi-disciplinary group of wound care stakeholders including payers, federal regulators such as the FDA, researchers, clinicians, and manufacturers to collaboratively discuss the challenges in wound care research, clinical care, and coverage. Specifically, stakeholder discussions focused on understanding the quantity and type of evidence payers need to make a coverage determination for wound care products and services, and how that evidence fulfills the requirements of federal regulators concerning safety and efficacy.
Dobson | DaVanzo staff are pleased to announce a recently accepted study in Advances in Wound Care, titled, "Cryopreserved placental membrane allograft reduces the likelihood of developing a new or recurring foot ulcer and all-cause mortality in diabetic patients, when compared to other cellular- and tissue-based products".
Using CMS Innovation Award Data, Dobson|DaVanzo is helping physicians and physician group practices “deep dive” into the complex world of MIPS VBP cost efficiency measures by dissecting risk-adjusted Medicare spending during episodes of care for 18 medical conditions/surgical procedures by clinical theme, type of service, and episode period (pre-, intra-, and post-trigger periods) compared to peer-group benchmarks. This allows providers to easily identify areas for improvement. Our monthly and quarterly data updates provide timely information that allows providers to continually monitor their performance trend overtime.
COVID-19 cases are currently on the decline in the U.S. and effective vaccines have been developed, approved and are being distributed at record pace – all cause for celebration. However, new variants and societal fatigue are continuing dangers to the health and well-being of Americans as the government and healthcare industry race to vaccinate and protect people from the novel pathogen. As we complete our first full year living in the COVID-19 public health emergency, this blog explores two questions worth asking:
- How far are we into this pandemic (in terms of herd immunity); and
- What are our policy options to take advantage of this recent decline in cases and steadily increasing availability of vaccines?